Reply to: "Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia-The SPASTOX Trial"
- PMID: 34302384
- DOI: 10.1002/mds.28658
Reply to: "Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia-The SPASTOX Trial"
Comment on
-
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.Mov Disord. 2021 Jul;36(7):1654-1663. doi: 10.1002/mds.28523. Epub 2021 Feb 17. Mov Disord. 2021. PMID: 33595142 Clinical Trial.
-
Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia-The SPASTOX Trial.Mov Disord. 2021 Jul;36(7):1733. doi: 10.1002/mds.28659. Mov Disord. 2021. PMID: 34302383 Free PMC article. No abstract available.
References
-
- Geva-Dayan K, Domenievitz D, Zahalka R, Fattal-Valevski A. Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis. J Child Neurol 2010;25(8):969-975.
-
- De Niet M, de Bot ST, van de Warrenburg BP, Weerdesteyn V, Geurts AC. Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: a study in patients with hereditary spastic paraplegia. J Rehabil Med 2015;47(2):147-153.
-
- Servelhere KR, Faber I, Martinez A, et al. Botulinum toxin for hereditary spastic paraplegia: effects motor and non-motor manifestations. Arq Neuropsiquiatr 2018;76(3):183-188.
-
- van Lith BJH, den Boer J, van de Warrenburg BPC, Weedersteyn V, Geurts AC. Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia. J Rehabil Med 2019;51(6):434-441.
-
- Paparella G, Vavla M, Bernardi L, Girardi G, Stefan C, Martinuzzi A. Efficacy of a combined treatment of Botulinum toxin and intensive physiotherapy in hereditary spastic paraplegia. Front Neurosci 2020;14:111.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical